What is your preferred first line therapy for advanced NSCLC with an EGFR activating mutation?

My current off-protocol approach is osimertinib as a single agent, though combining osimertinib with bevacizumab is being tested in an interesting clinical trial. The bev-erlo combination trials are very small with small hints of a survival benefit, but definitely improved progression-free survival....